An announcement from Masimo ( (MASI)) is now available. On May 1, 2026, Masimo shareholders approved the company’s merger agreement with Danaher Corporation at a virtual special meeting, with roughly ...

Masimo Corporation (Nasdaq: MASI) ("Masimo"), a leading global innovator in patient monitoring, today announced that its stockholders voted in favor of the proposal to ...

Masimo Corporation (Nasdaq: MASI) ("Masimo"), a leading global innovator in patient monitoring, today announced that its stockholders voted in favor of the proposal to adopt the previously announced ...

Is MASI a good stock to buy? We came across a bullish thesis on Masimo Corporation on Valueinvestorsclub.com by GCA. In this ...

Masimo’s NeoPODS study in critically ill newborns found its SET pulse oximetry technology delivered consistent accuracy across all skin tones, with less than 1% bias. The findings address longstanding ...

Masimo MASI recently reported findings from the NeoPODS study, a large prospective real-world evaluation of its SET pulse oximetry technology in critically ill newborns. The study demonstrated less ...

These promising results—from an NIH-funded study that exclusively evaluated Masimo SET ® in a vulnerable, clinically fragile ...

Masimo (NASDAQ: MASI) today announced the findings of a study evaluating the accuracy of Masimo SET ® pulse oximetry among critically ill neonates and demonstrating less than 1% overall statistical ...

NICU Study Adds to the Evidence Demonstrating SET®’s Accuracy in Challenging Real-World Settings, With No Clinically Significant Differences in Performance Across Skin Pigmentation Categories or Race ...

The SET pulse oximetry technology used with a neonate. [Image courtesy of Masimo] Masimo (Nasdaq:MASI) today announced new study findings supporting the use of its SET pulse oximetry in critically ill ...